吉非替尼的临床应用研究

Clinical application of Gefitinib

吉非替尼为靶向性表皮生长因子受体(EGFR)酪氨酸激酶抑制剂,2005年批准进口中国用于治疗局部晚期及或转移性非小细胞肺癌(NSCLC),其疗效好且血液系统不良反应较少,最常见的不良反应为腹泻和皮肤反应。2015年7月13日,美国食品药品监督管理局批准吉非替尼用于转移性非小细胞肺癌靶向性表皮生长因子受体基因突变的患者。本文主要综述了其近年国内外的临床研究进展。

Gefitinib is an EGFR inhibitor.It is only effective in cancers with mutated and overactive EGFR.The CFDA approved gefitinib in 2005 for non-small cell lung cancer{ NSCLC} .It was approved as monotherapy for the treatment of pa- tients with locally advanced or metastatic NSCLC after failure of both platinum-based and docetaxel ehemotherapies.On July 13,2015 ,FDA approved as a first-line treatment for NSCLC.The advancement of gefitinib in current clinic researches were reviewed in this article.